Patent · US Active

Hepatitis D virus (HDV) iRNA compositions and methods of use thereof

US10640770B2 · kind B2 · utility

0Cited by

6References

24Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Gregory Hinkle · Plymouth, US
Laura Sepp-Lorenzino · Benson East, US
Vasant Jadhav · Cambridge, US
Martin Maier · Cambridge, US
Muthiah Manoharan · Carlsbad, US
Stuart Milstein · Cambridge, US
Svetlana Shulga Morskaya · Sudbury, US
Kallanthottathil G. Rajeev · Wayland, US
Huilei Xu · Boston, US

Key dates

Filing date	May 10, 2017
Grant date	May 5, 2020
Priority date	—
Expiry date	May 10, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.